JP7642531B2 - プログラム可能塩基エディターシステムを用いて病原性アミノ酸を置換する方法 - Google Patents

プログラム可能塩基エディターシステムを用いて病原性アミノ酸を置換する方法 Download PDF

Info

Publication number
JP7642531B2
JP7642531B2 JP2021513763A JP2021513763A JP7642531B2 JP 7642531 B2 JP7642531 B2 JP 7642531B2 JP 2021513763 A JP2021513763 A JP 2021513763A JP 2021513763 A JP2021513763 A JP 2021513763A JP 7642531 B2 JP7642531 B2 JP 7642531B2
Authority
JP
Japan
Prior art keywords
amino acid
cas9
domain
polynucleotide
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021513763A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523737A (ja
JP2021523737A5 (https=
Inventor
デイビッド ブライソン、
ジョン エヴァンス、
マイケル パッカー、
ヤンファン フ、
ニコル ゴーデッリ、
ジェイソン マイケル ゲールケ、
ジェイ． キース ジョン、
Original Assignee
ビーム セラピューティクス インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビーム セラピューティクス インク． filed Critical ビーム セラピューティクス インク．
Publication of JP2021523737A publication Critical patent/JP2021523737A/ja
Publication of JP2021523737A5 publication Critical patent/JP2021523737A5/ja
Priority to JP2024183249A priority Critical patent/JP2025026840A/ja
Application granted granted Critical
Publication of JP7642531B2 publication Critical patent/JP7642531B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04004—Adenosine deaminase (3.5.4.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021513763A 2018-05-11 2019-05-11 プログラム可能塩基エディターシステムを用いて病原性アミノ酸を置換する方法 Active JP7642531B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024183249A JP2025026840A (ja) 2018-05-11 2024-10-18 プログラム可能塩基エディターシステムを用いて病原性アミノ酸を置換する方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862670539P 2018-05-11 2018-05-11
US201862670521P 2018-05-11 2018-05-11
US62/670,521 2018-05-11
US62/670,539 2018-05-11
US201862780890P 2018-12-17 2018-12-17
US62/780,890 2018-12-17
PCT/US2019/031897 WO2019217942A1 (en) 2018-05-11 2019-05-11 Methods of substituting pathogenic amino acids using programmable base editor systems

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024183249A Division JP2025026840A (ja) 2018-05-11 2024-10-18 プログラム可能塩基エディターシステムを用いて病原性アミノ酸を置換する方法

Publications (3)

Publication Number Publication Date
JP2021523737A JP2021523737A (ja) 2021-09-09
JP2021523737A5 JP2021523737A5 (https=) 2022-05-19
JP7642531B2 true JP7642531B2 (ja) 2025-03-10

Family

ID=68467606

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021513763A Active JP7642531B2 (ja) 2018-05-11 2019-05-11 プログラム可能塩基エディターシステムを用いて病原性アミノ酸を置換する方法
JP2024183249A Pending JP2025026840A (ja) 2018-05-11 2024-10-18 プログラム可能塩基エディターシステムを用いて病原性アミノ酸を置換する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024183249A Pending JP2025026840A (ja) 2018-05-11 2024-10-18 プログラム可能塩基エディターシステムを用いて病原性アミノ酸を置換する方法

Country Status (8)

Country Link
US (2) US12133884B2 (https=)
EP (1) EP3799603A4 (https=)
JP (2) JP7642531B2 (https=)
KR (2) KR20250134703A (https=)
CN (2) CN121555430A (https=)
AU (2) AU2019265019B2 (https=)
CA (1) CA3100019A1 (https=)
WO (1) WO2019217942A1 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
IL310721B2 (en) 2015-10-23 2025-11-01 Harvard College Nucleobase editors and uses thereof
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
US12390514B2 (en) 2017-03-09 2025-08-19 President And Fellows Of Harvard College Cancer vaccine
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
KR20250107288A (ko) 2017-10-16 2025-07-11 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
AU2019265019B2 (en) 2018-05-11 2025-11-06 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
EP3847254A4 (en) 2018-09-07 2022-08-10 Beam Therapeutics Inc. COMPOSITIONS AND METHODS FOR DELIVERING A NUCLEOBASE EDITING SYSTEM
WO2020051562A2 (en) 2018-09-07 2020-03-12 Beam Therapeutics Inc. Compositions and methods for improving base editing
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
CN120174005A (zh) 2019-02-13 2025-06-20 比姆医疗股份有限公司 具有用于修饰靶标序列中核碱基的腺苷脱氨酶碱基编辑器的经修饰的免疫细胞
CA3128755C (en) 2019-02-13 2024-06-04 Beam Therapeutics Inc. Compositions and methods for treating hemoglobinopathies
WO2020191233A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
EP4034138A4 (en) 2019-09-27 2024-07-31 Beam Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
IL292517A (en) * 2019-12-17 2022-06-01 Sigma Aldrich Co Llc Genome editing in Bacteroidetes
WO2021151085A2 (en) 2020-01-24 2021-07-29 The General Hospital Corporation Crispr-cas enzymes with enhanced on-target activity
WO2021151073A2 (en) 2020-01-24 2021-07-29 The General Hospital Corporation Unconstrained genome targeting with near-pamless engineered crispr-cas9 variants
WO2021163587A1 (en) * 2020-02-13 2021-08-19 Beam Therapeutics Inc. Compositions and methods for engraftment of base edited cells
US12416001B2 (en) * 2020-02-14 2025-09-16 Ohio State Innovation Foundation Nucleobase editors and methods of use thereof
WO2021183504A1 (en) * 2020-03-11 2021-09-16 North Carolina State University Compositions, methods, and systems for genome editing technology
EP4143315A1 (en) 2020-04-28 2023-03-08 The Broad Institute Inc. <smallcaps/>? ? ?ush2a? ? ? ? ?targeted base editing of thegene
IL297761A (en) 2020-05-08 2022-12-01 Broad Inst Inc Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence
US20230279438A1 (en) * 2020-05-13 2023-09-07 Inserm (Institut National De La Santé Et La Recherche Médicale) Base editing approaches for the treatment of betahemoglobinopathies
CA3196831A1 (en) 2020-09-25 2022-03-31 Beam Therapeutics Inc. Fratricide resistant modified immune cells and methods of using the same
WO2022119294A1 (ko) * 2020-12-01 2022-06-09 한양대학교 산학협력단 사이토신 교정 활성이 제거된 아데닌 염기교정 유전자가위 및 이의 용도
JP2024502348A (ja) * 2021-01-05 2024-01-18 ホライズン・ディスカバリー・リミテッド Ｔｒａｃｒ不含 Ｖ型Ｃａｓシステム用のガイドＲＮＡデザインおよび複合体
WO2022150372A1 (en) * 2021-01-05 2022-07-14 Horizon Discovery Ltd. Guide rna designs and complexes for type v cas systems
WO2022206986A1 (en) * 2021-04-02 2022-10-06 Shanghaitech University Gene therapy for treating beta-hemoglobinopathies
AU2022272250A1 (en) * 2021-05-14 2023-11-30 Beam Therapeutics Inc. Compositions and methods for treating transthyretin amyloidosis
JP7125727B1 (ja) * 2021-09-07 2022-08-25 国立大学法人千葉大学 核酸配列改変用組成物および核酸配列の標的部位を改変する方法
WO2023056139A1 (en) * 2021-10-01 2023-04-06 The Regents Of The University Of California Compositions and methods for treating a β-thalassemia disease
WO2024018056A1 (en) * 2022-07-22 2024-01-25 Institut National de la Santé et de la Recherche Médicale Base editing approaches for correcting the ivs2-1 (g>a) mutation in patients suffering from βeta-thalassemia
AU2024301706A1 (en) * 2023-07-21 2026-02-05 Crispr Therapeutics Ag Modulating expression of alas1 (5'-aminolevulinate synthase 1) gene
CN120813698A (zh) * 2023-09-22 2025-10-17 北京大学现代农业研究院 改进的基因组编辑方法
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016528890A (ja) 2013-07-09 2016-09-23 プレジデント アンド フェローズ オブ ハーバード カレッジ ＣＲＩＳＰＲ／Ｃａｓ系を用いるゲノム編集の治療用の使用

Family Cites Families (321)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0329734A (ja) 1989-06-20 1991-02-07 Kubota Corp ラベルプリンタ
US7144731B2 (en) 1989-10-16 2006-12-05 Amgen Inc. SCF antibody compositions and methods of using the same
US20050276784A1 (en) 1990-08-27 2005-12-15 Solan-Kettering Institute For Cancer Research Ligand for the c-kit receptor and methods of use thereof
DE4205148A1 (de) 1991-05-25 1993-01-21 Boehringer Mannheim Gmbh Monoklonale antikoerper gegen c-kit
WO1994008039A1 (en) 1992-10-02 1994-04-14 Systemix, Inc. Method of enrichment for human hematopoietic stem cells using c-kit
US5821108A (en) 1995-04-07 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Enrichment for a thymocyte subset having progenitor cell activity using c-kit as a selection marker
CN1173776C (zh) 1996-06-28 2004-11-03 卡钳技术有限公司 在微规模流体性设备里的高通过量的筛选分析系统
US6555367B1 (en) 1997-10-10 2003-04-29 The United States Of America As Represented By The Department Of Health And Human Services Complex of biotinylated viral vector and ligand for targeted gene delivery
JP2002516085A (ja) 1998-05-29 2002-06-04 トーマス・ジェファーソン・ユニバーシティ 哺乳動物における造血幹細胞集団に影響を及ぼす組成物および使用法
DE69929059T2 (de) 1998-07-31 2006-08-24 Mitsubishi Chemical Corp. Verfahren zum bestimmen von physiologisch aktiven komponenten
US6989248B2 (en) 1999-05-06 2006-01-24 The Trustees Of Columbia University In The City Of New York Methods of use of compounds which inhibit the stem cell signaling pathway
EP1235914A2 (en) 1999-11-24 2002-09-04 Joseph Rosenecker Polypeptides comprising multimers of nuclear localization signals or of protein transduction domains and their use for transferring molecules into cells
US20030082155A1 (en) 1999-12-06 2003-05-01 Habener Joel F. Stem cells of the islets of langerhans and their use in treating diabetes mellitus
US7862810B2 (en) 2000-07-31 2011-01-04 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US20040003420A1 (en) 2000-11-10 2004-01-01 Ralf Kuhn Modified recombinase
US20050222030A1 (en) 2001-02-21 2005-10-06 Anthony Allison Modified annexin proteins and methods for preventing thrombosis
WO2002068676A2 (en) 2001-02-27 2002-09-06 University Of Rochester METHODS AND COMPOSITIONS FOR MODIFYING APOLIPOPROTEIN B mRNA EDITING
CN100516204C (zh) 2001-04-24 2009-07-22 味之素株式会社 干细胞及其分离方法
AU2002330714A1 (en) 2001-05-30 2003-01-02 Biomedical Center In silico screening for phenotype-associated expressed sequences
WO2003016867A2 (en) 2001-08-21 2003-02-27 Ventana, Medical, Systems, Inc Method and quantification assay for determining c-kit/scf/pakt status
EP1442115B9 (en) 2001-11-15 2009-12-16 Children's Medical Center Corporation Methods of isolation, expansion and differentiation of fetal stem cells from chorionic villus, amniotic fluid, and placenta and therapeutic uses thereof
WO2003065881A2 (en) 2002-02-06 2003-08-14 Orbus Medical Technologies Inc. Medical device with coating that promotes endothelial cell adherence and differentiation
US20040161419A1 (en) 2002-04-19 2004-08-19 Strom Stephen C. Placental stem cells and uses thereof
EP1622645B1 (en) 2002-04-23 2013-10-23 Roger Williams Hospital Compositions and methods for stem cell delivery
US20040005623A1 (en) 2002-06-10 2004-01-08 Longley B. Jack Method of determining tumor sensitivities to therapeutic drugs
AU2003245752A1 (en) 2002-06-28 2004-01-19 Bio Transplant, Inc. Process for promoting graft acceptance by depletion of hematopoietic stem cells
WO2004005531A2 (en) 2002-07-05 2004-01-15 Roger Williams Medical Center Targeting and tracking of cells to specific organs and tissues in vivo
US20050032122A1 (en) 2003-08-06 2005-02-10 Shiaw-Min Hwang Optimizing culture medium for CD34<+> hematopoietic cell expansion
US20050124896A1 (en) 2003-08-25 2005-06-09 Jacob Richter Method for protecting implantable sensors and protected implantable sensors
US20080085902A1 (en) 2003-09-23 2008-04-10 Guido Bold Combination Of A Vegf Receptor Inhibitor Or With A Chemotherapeutic Agent
TWI338714B (en) 2003-12-02 2011-03-11 Cathay General Hospital Method of isolation and enrichment of mesenchymal stem cells from amniotic fluid
CA2556018A1 (en) 2004-02-11 2005-09-09 Aldagen, Inc. Stem cell populations and methods of use
US20050187607A1 (en) 2004-02-20 2005-08-25 Akhtar Adil J. Drug delivery device
WO2005100999A2 (en) 2004-04-08 2005-10-27 Cornell Research Foundation, Inc. Functional immunohistochemical cell cycle analysis as a prognostic indicator for cancer
WO2006031524A2 (en) 2004-09-10 2006-03-23 The Regents Of The Unversity Of Colorado Early detection of hemangiosarcoma and angiosarcoma
WO2006062946A2 (en) 2004-12-06 2006-06-15 University Of Florida Research Foundation, Inc. Incorporation of bone marrow derived stem cells in tumors
CA2593549C (en) 2005-01-07 2016-04-26 Wake Forest University Health Sciences Regeneration of pancreatic islets by amniotic fluid stem cell therapy
WO2006089048A2 (en) 2005-02-16 2006-08-24 Hemogenix, Inc. Methods of screening compounds to predict toxicity and residual proliferative and differentiation capacity of the lympho-hematopoietic system
US20060222634A1 (en) 2005-03-31 2006-10-05 Clarke Diana L Amnion-derived cell compositions, methods of making and uses thereof
PL1874821T3 (pl) 2005-04-26 2013-09-30 Trion Pharma Gmbh Kombinacja przeciwciał i glikokortykoidów do leczenia raka
US20070041948A1 (en) 2005-07-20 2007-02-22 Seoul National University Industry Foundation Method for culturing and proliferating hematopoietic stem cells and progenitor cells using human endometrial cells
EP1948827B1 (en) 2005-10-21 2016-03-23 The Regents of The University of California C-kit oncogene mutations in melanoma
AU2006309551B2 (en) 2005-11-07 2012-04-19 Eisai R & D Management Co., Ltd. Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
US20090304625A1 (en) 2006-01-18 2009-12-10 Ahsan Husain Modulators of cardiac cell hypertrophy and hyperplasia
WO2007118242A2 (en) 2006-04-07 2007-10-18 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Identification of a constitutively resistant cancer stem cell
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
US8568286B2 (en) 2006-06-14 2013-10-29 Cardiac Pacemakers, Inc. Methods to position therapeutic agents using a magnetic field
WO2008067115A2 (en) 2006-11-03 2008-06-05 The Board Of Trustees Of The Leland Stanford Junior University Selective immunodepletion of endogenous stem cell niche for engraftment
US20100143935A1 (en) 2006-12-01 2010-06-10 Apocell, Inc. c-KIT Phosphorylation in Cancer
WO2008076143A1 (en) 2006-12-18 2008-06-26 Osi Pharmaceuticals, Inc. Combination of igfr inhibitor and anti-cancer agent
US8865159B2 (en) 2007-01-04 2014-10-21 Cold Spring Harbor Laboratory Treatment of tumors by ablating bone marrow-derived endothelial progenitor cells
DE102007008650B4 (de) 2007-02-20 2012-06-06 Charité - Universitätsmedizin Berlin Zellen zur Therapie des Herzens
TW200902718A (en) 2007-03-01 2009-01-16 Cryo Cell Int Procurement, isolation, and cryopreservation of endometrial/menstrual cells
US9200253B1 (en) 2007-08-06 2015-12-01 Anthrogenesis Corporation Method of producing erythrocytes
WO2009058983A2 (en) 2007-10-30 2009-05-07 University Of Louisville Research Foundation, Inc. Subpopulations of bone marrow-derived adherent stem cells and methods of use therefor
US20090169613A1 (en) 2007-11-09 2009-07-02 Reznik Boris N Targeting of tumor stem cells through selective silencing of boris expression
AU2009307651A1 (en) 2008-10-22 2010-04-29 Genentech, Inc. Prostate stem cells and uses thereof
AU2010229924B2 (en) 2009-03-24 2016-07-21 Plus Therapeutics Inc. Devices and methods of cell capture and analysis
BRPI1013177A2 (pt) 2009-05-28 2016-04-12 Glaxo Group Ltd construto de ligação de antígeno, polipeptídeo isolado, e, método para tratar doença cardíaca
EP2259065A1 (en) 2009-06-03 2010-12-08 Erasmus University Medical Center Rotterdam Methods, reagents and kits for flow cytometric immunophenotyping
WO2013166281A1 (en) 2012-05-02 2013-11-07 Cedars-Sinai Medical Center Bi-functional compositions for targeting cells to diseased tissues and methods of using same
US20110104787A1 (en) 2009-11-05 2011-05-05 President And Fellows Of Harvard College Fusion Peptides That Bind to and Modify Target Nucleic Acid Sequences
WO2011057216A1 (en) 2009-11-06 2011-05-12 The Pennsylvania State Research Foundation Bioconjugation of calcium phosphosilicate nanoparticles for selective targeting of cells in vivo
US8518716B2 (en) 2009-11-30 2013-08-27 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Soluble CD117 (sc-kit) for diagnosis of preeclampsia and eclampsia
WO2011073521A1 (en) 2009-12-15 2011-06-23 Petri Salven Methods for enriching adult-derived endothelial progenitor cells and uses thereof
EP2513296A4 (en) 2009-12-18 2013-05-22 Univ Leland Stanford Junior USE OF CYTIDINE DAMINASE ASSOCIATED ACTIVITIES TO PROMOTE DEMETHYLATION AND CELL REPROGRAMMEIRING
BR112012017084A2 (pt) 2010-01-12 2016-04-12 Nestec Sa métodos para previsão de resposta de câncer de mama triplo-negativo à terapia
WO2012004778A1 (en) 2010-07-09 2012-01-12 Ecole Polytechnique Federale De Lausanne (Epfl) Method for in-vitro monitoring of neuronal disorders and use thereof
EP2624847B1 (en) 2010-10-05 2017-09-13 AAL Scientifics, Inc. Human lung stem cells and uses thereof
WO2012068243A2 (en) 2010-11-16 2012-05-24 Ingeneron, Inc. Methods for obtaining target cells
WO2012068248A2 (en) 2010-11-16 2012-05-24 Ingeneron, Inc. Methods for preserving target cells
WO2012135844A2 (en) 2011-04-01 2012-10-04 Cornell University Circulating exosomes as diagnostic/prognostic indicators and therapeutic targets of melanoma and other cancers
WO2012142411A1 (en) 2011-04-15 2012-10-18 Clavis Pharma Asa Systems and methods for detecting hent1 expression in hematological disorders
CA2835601C (en) 2011-05-11 2019-09-10 Stemrad Ltd. Radiation protection device and methods thereof
AR086044A1 (es) 2011-05-12 2013-11-13 Imclone Llc Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
CA2806625A1 (en) 2011-06-14 2012-12-20 Mickie Bhatia Isolated embryonic stem cells that express lineage markers and associated methods
CN102876666B (zh) 2011-07-15 2015-02-04 内蒙古弘泰医学科技有限公司 Rna胞体及其用途
CN103088008B (zh) 2011-10-31 2014-08-20 中国科学院微生物研究所 胞苷脱氨酶及其编码基因和它们的应用
US20150166969A1 (en) 2012-02-24 2015-06-18 Fred Hutchinson Cancer Research Center Compositions and methods for the treatment of hemoglobinopathies
KR101384360B1 (ko) 2012-05-04 2014-04-14 아주대학교산학협력단 Ｓｃｆ 또는 이의 수용체를 억제하는 물질을 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물
AU2013266968B2 (en) 2012-05-25 2017-06-29 Emmanuelle CHARPENTIER Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
WO2013188037A2 (en) 2012-06-11 2013-12-19 Agilent Technologies, Inc Method of adaptor-dimer subtraction using a crispr cas6 protein
WO2013187765A2 (en) 2012-06-14 2013-12-19 Erasmus University Medical Center Rotterdam Methods, reagents and kits for detecting minimal residual disease
EP3431497B1 (en) 2012-06-27 2022-07-27 The Trustees of Princeton University Split inteins, conjugates and uses thereof
SG10201701601WA (en) 2012-08-29 2017-04-27 Sangamo Biosciences Inc Methods and compositions for treatment of a genetic condition
WO2014043442A1 (en) 2012-09-14 2014-03-20 Children's Medical Center Corporation Inhibition of viral infection-triggered asthma with c-kit inhibitor
JP2015529466A (ja) 2012-09-14 2015-10-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 鎌状赤血球症の幹細胞遺伝子治療のためのレンチウイルスベクター
CA2886607A1 (en) 2012-10-17 2014-04-24 Cedars-Sinai Medical Center Molecular signatures of ovarian cancer
US20150299315A1 (en) 2012-10-22 2015-10-22 Becton, Dickinson And Company Non-b-lineage cells capable of producing antibody
EP2914273B1 (en) 2012-10-26 2018-07-04 Cedars-Sinai Medical Center Therapeutic cells depleted of specific subpopulations of cells for use in tissue repair of regeneration
WO2014081712A2 (en) 2012-11-20 2014-05-30 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with bruton's tyrosine kinase
PL3360964T3 (pl) 2012-12-06 2020-03-31 Sigma-Aldrich Co. Llc Modyfikacja i regulacja genomu oparta na crispr
WO2014093655A2 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
EP3031921B1 (en) 2012-12-12 2025-03-12 The Broad Institute, Inc. Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
DK2931891T3 (da) 2012-12-17 2019-08-19 Harvard College Rna-styret modificering af menneskelige genomer
US20210137991A1 (en) 2013-02-08 2021-05-13 Themba Inc. Gene editing for autoimmune disorders
EP2970985A1 (en) 2013-03-14 2016-01-20 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
WO2014141306A2 (en) 2013-03-15 2014-09-18 Rajiv Gandhi Centre For Biotechnology Methods and materials for identifying therapeutic response in chronic myeloid leukemia
US20140273230A1 (en) 2013-03-15 2014-09-18 Sigma-Aldrich Co., Llc Crispr-based genome modification and regulation
CN112301024A (zh) 2013-03-15 2021-02-02 通用医疗公司 使用RNA引导的FokI核酸酶(RFN)提高RNA引导的基因组编辑的特异性
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
WO2014186686A2 (en) 2013-05-17 2014-11-20 Two Blades Foundation Targeted mutagenesis and genome engineering in plants using rna-guided cas nucleases
US9267135B2 (en) 2013-06-04 2016-02-23 President And Fellows Of Harvard College RNA-guided transcriptional regulation
WO2014197748A2 (en) 2013-06-05 2014-12-11 Duke University Rna-guided gene editing and gene regulation
WO2014197821A1 (en) 2013-06-06 2014-12-11 President And Fellows Of Harvard College Homeodomain fusion proteins and uses thereof
CA2917348A1 (en) 2013-07-11 2015-01-15 Moderna Therapeutics, Inc. Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
FR3008408B1 (fr) 2013-07-11 2018-03-09 Mc Saf Nouveaux conjugues anticorps-medicament et leur utilisation en therapie
WO2015021426A1 (en) 2013-08-09 2015-02-12 Sage Labs, Inc. A crispr/cas system-based novel fusion protein and its application in genome editing
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
CN106459995B (zh) 2013-11-07 2020-02-21 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
JP7103750B2 (ja) 2013-12-12 2022-07-20 ザ・ブロード・インスティテュート・インコーポレイテッド ゲノム編集のためのＣＲＩＳＰＲ－Ｃａｓ系及び組成物の送達、使用及び治療適用
EP3835419A1 (en) 2013-12-12 2021-06-16 The Regents of The University of California Methods and compositions for modifying a single stranded target nucleic acid
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
JP6793547B2 (ja) 2013-12-12 2020-12-02 ザ・ブロード・インスティテュート・インコーポレイテッド 最適化機能ＣＲＩＳＰＲ−Ｃａｓ系による配列操作のための系、方法および組成物
WO2015148512A1 (en) 2014-03-24 2015-10-01 Qt Holdings Corp Shaped articles including hydrogels and methods of manufacture and use thereof
US10369104B2 (en) 2014-04-01 2019-08-06 Children's Hospital Los Angeles Targeted polymerized nanoparticles for cancer treatment
EP3155116A4 (en) 2014-06-10 2017-12-27 Massachusetts Institute Of Technology Method for gene editing
EP4257145B1 (en) 2014-08-26 2025-06-25 The Board of Trustees of the Leland Stanford Junior University Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling
EP3186375A4 (en) 2014-08-28 2019-03-13 North Carolina State University Novel CAS9 PROTEINS AND CHARACTERISTICS FOR DNA TARGETING AND GENOME EDITING
EP2995948A1 (en) 2014-09-09 2016-03-16 Ecole Polytechnique Federale de Lausanne (EPFL) Methods and compounds useful in hematopoietic stem cell medicine
WO2016049258A2 (en) 2014-09-25 2016-03-31 The Broad Institute Inc. Functional screening with optimized functional crispr-cas systems
BR112017007765B1 (pt) 2014-10-14 2023-10-03 Halozyme, Inc Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
US10258697B2 (en) 2014-10-29 2019-04-16 Massachusetts Eye And Ear Infirmary Efficient delivery of therapeutic molecules in vitro and in vivo
PT3216867T (pt) 2014-11-04 2020-07-16 Univ Kobe Nat Univ Corp Método para modificar a sequência de genoma para introduzir mutação específica a sequência de adn alvo por reação de remoção de bases, e complexo molecular nele utilizado
EP3224617A1 (en) 2014-11-26 2017-10-04 Oxford University Innovation Limited Detection of acute myeloid leukaemia (aml) leukaemic stem cells (lsc)
WO2016094872A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Dead guides for crispr transcription factors
EP3234134B1 (en) 2014-12-17 2020-05-27 ProQR Therapeutics II B.V. Targeted rna editing
BR112017017812A2 (en) 2015-02-23 2018-04-10 Crispr Therapeutics Ag Materials and methods for treatment of hemoglobinopathies
WO2016135559A2 (en) 2015-02-23 2016-09-01 Crispr Therapeutics Ag Materials and methods for treatment of human genetic diseases including hemoglobinopathies
KR20230156800A (ko) 2015-03-03 2023-11-14 더 제너럴 하스피탈 코포레이션 변경된 PAM 특이성을 갖는 조작된 CRISPR-Cas9 뉴클레아제
CN107614531A (zh) 2015-03-18 2018-01-19 纪念斯隆凯特琳癌症中心 在造血和淋巴恶性肿瘤中靶向cd99的组合物和方法
HK1256681A1 (zh) 2015-04-06 2019-10-04 President And Fellows Of Harvard College 用於非清髓性预处理的组合物和方法
WO2016183236A1 (en) 2015-05-11 2016-11-17 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating hiv infection and aids
CN106011104B (zh) 2015-05-21 2019-09-27 清华大学 利用拆分Cas系统进行基因编辑和表达调控方法
WO2016205759A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
US9957501B2 (en) 2015-06-18 2018-05-01 Sangamo Therapeutics, Inc. Nuclease-mediated regulation of gene expression
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
JP7044373B2 (ja) 2015-07-15 2022-03-30 ラトガース，ザ ステート ユニバーシティ オブ ニュージャージー ヌクレアーゼ非依存的な標的化遺伝子編集プラットフォームおよびその用途
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US11008555B2 (en) 2015-09-17 2021-05-18 The Regents Of The University Of California Variant Cas9 polypeptides comprising internal insertions
EP3356520B1 (en) 2015-10-02 2022-03-23 The U.S.A. as represented by the Secretary, Department of Health and Human Services Lentiviral protein delivery system for rna-guided genome editing
IL310721B2 (en) 2015-10-23 2025-11-01 Harvard College Nucleobase editors and uses thereof
US12043843B2 (en) 2015-11-04 2024-07-23 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of hemoglobinopathies
BR112018008971A2 (pt) 2015-11-06 2018-11-27 Crispr Therapeutics Ag materiais e métodos para tratamento de doença de armazenamento de glicogênio tipo 1a
CN109715801B (zh) 2015-12-01 2022-11-01 克里斯普治疗股份公司 用于治疗α1抗胰蛋白酶缺乏的材料和方法
JP2019508051A (ja) 2016-03-14 2019-03-28 エディタス・メディシン、インコーポレイテッド β異常ヘモグロビン症を治療するためのＣＲＩＳＰＲ／ＣＡＳ関連方法および組成物
US11512311B2 (en) 2016-03-25 2022-11-29 Editas Medicine, Inc. Systems and methods for treating alpha 1-antitrypsin (A1AT) deficiency
LT3436077T (lt) 2016-03-30 2025-06-25 Intellia Therapeutics, Inc. Lipidų nanodalelių vaisto formos, skirtos crispr/cas komponentams
EP4711465A2 (en) 2016-04-14 2026-03-18 Fred Hutchinson Cancer Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
JP2019103391A (ja) 2016-04-14 2019-06-27 国立大学法人 東京医科歯科大学 単球系統のみに分化するヒト単球前駆細胞およびその単離方法
AU2017257274B2 (en) 2016-04-19 2023-07-13 Massachusetts Institute Of Technology Novel CRISPR enzymes and systems
KR20260004568A (ko) 2016-04-19 2026-01-08 더 브로드 인스티튜트, 인코퍼레이티드 신규한 crispr 효소 및 시스템
WO2017191503A1 (en) 2016-05-05 2017-11-09 Crispr Therapeutics Ag Materials and methods for treatment of hemoglobinopathies
FR3051555B1 (fr) 2016-05-20 2018-05-11 Horiba Abx Sas Detection de la maladie residuelle du myelome multiple
EP3463318A4 (en) 2016-05-27 2020-01-01 TG Therapeutics Inc. COMBINATION OF ANTI-CD20-ANTIBODIES, P13-KINASE-DELTA-SELECTIVE INHIBITOR AND BTK-INHIBITOR FOR THE TREATMENT OF PROLIFERATIVE B-CELL DISORDERS
US10767175B2 (en) 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
IL263744B2 (en) 2016-06-17 2023-11-01 Magenta Therapeutics Inc Compositions and methods for the depletion of cd117 plus cells
CN109641051A (zh) 2016-06-17 2019-04-16 美真达治疗公司 用于耗尽细胞的组合物和方法
WO2018020323A2 (en) 2016-07-25 2018-02-01 Crispr Therapeutics Ag Materials and methods for treatment of fatty acid disorders
CN110214183A (zh) 2016-08-03 2019-09-06 哈佛大学的校长及成员们 腺苷核碱基编辑器及其用途
KR102546839B1 (ko) 2016-08-03 2023-06-23 워싱턴 유니버시티 키메라 항원 수용체를 이용한 t 세포 악성종양의 치료를 위한 car-t 세포의 유전자 편집
WO2018031683A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
EP4485466A3 (en) 2016-08-17 2025-04-02 The Broad Institute Inc. Novel crispr enzymes and systems
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
EP3500663A1 (en) 2016-08-29 2019-06-26 PDI Pharm Development International AG Provision of a therapeutically active cell product
CN110352244B (zh) 2016-09-01 2023-03-21 ProQR治疗上市公司Ⅱ 化学修饰的编辑rna的单链寡核苷酸
EP3509635A1 (en) 2016-09-06 2019-07-17 Vavotar Life Sciences LLC Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
KR102622411B1 (ko) 2016-10-14 2024-01-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
LT3535392T (lt) 2016-11-02 2024-04-25 Universität Basel Imunologiškai atpažįstami ląstelių paviršiaus variantai, skirti naudoti ląstelių terapijoje
WO2018085516A2 (en) 2016-11-02 2018-05-11 Aal Scientifics, Inc. Non-mesenchymal human lung stem cells and methods of their use for treating respiratory diseases
EP3538561A4 (en) 2016-11-11 2020-10-21 The Regents of The University of California RNA-GUIDED VARIANT POLYPEPTIDES AND THEIR METHODS OF USE
CN107043779B (zh) 2016-12-01 2020-05-12 中国农业科学院作物科学研究所 一种CRISPR/nCas9介导的定点碱基替换在植物中的应用
SG10202106058WA (en) 2016-12-08 2021-07-29 Intellia Therapeutics Inc Modified guide rnas
TWI851534B (zh) 2016-12-22 2024-08-11 美商英特利亞醫療公司 用於治療α-１抗胰蛋白酶缺乏症之組合物及方法
KR20230125856A (ko) 2016-12-23 2023-08-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Pcsk9의 유전자 편집
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
EP3401834B1 (en) 2016-12-26 2022-08-17 Shenzhen Goodix Technology Co., Ltd. Fingerprint recognition system
EP3565608A4 (en) 2017-01-05 2020-12-16 Rutgers, The State University of New Jersey TARGETED GENE EDITING PLATFORM INDEPENDENT OF BICATENARY DNA BREAKAGE AND ITS USES
EP3571230A4 (en) 2017-01-20 2020-12-16 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DELETION OF CD137 + CELLS
KR20190109440A (ko) 2017-01-30 2019-09-25 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 줄기 세포 이식을 위한 비-유전독성 컨디셔닝 레지멘
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
WO2018152197A1 (en) 2017-02-15 2018-08-23 Massachusetts Institute Of Technology Dna writers, molecular recorders and uses thereof
RU2019130504A (ru) 2017-02-28 2021-03-30 Вор Байофарма, Инк. Композиции и способы ингибирования линиеспецифических белков
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
WO2018170184A1 (en) 2017-03-14 2018-09-20 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
KR20240116572A (ko) 2017-03-23 2024-07-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
WO2018183613A1 (en) 2017-03-31 2018-10-04 The Children's Medical Center Corporation Antibody-mediated conditioning with immunosuppression to enable allogeneic transplantation
CN106916852B (zh) 2017-04-13 2020-12-04 上海科技大学 一种碱基编辑系统及其构建和应用方法
WO2018191746A1 (en) 2017-04-14 2018-10-18 Bolt Biotherapeutics, Inc. Immunoconjugate synthesis method
US11591589B2 (en) 2017-04-21 2023-02-28 The General Hospital Corporation Variants of Cpf1 (Cas12a) with altered PAM specificity
WO2018213726A1 (en) 2017-05-18 2018-11-22 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
US11866697B2 (en) 2017-05-18 2024-01-09 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
EP3630849A4 (en) 2017-05-25 2021-01-13 The General Hospital Corporation BIPARTITE BASIC EDITOR (BBE) AND TYPE II-C-CAS9 ZINC FINGER EDITOR ARCHITECTURES
IT201700062176A1 (it) 2017-06-07 2018-12-07 Univ Degli Studi Milano Metodo per l’isolamento di sottopopolazioni di progenitori cellulari cardiaci e relativi usi in campo medico
WO2019005886A1 (en) 2017-06-26 2019-01-03 The Broad Institute, Inc. CRISPR / CAS-CYTIDINE DEAMINASE COMPOSITIONS, SYSTEMS AND METHODS FOR TARGETED EDITING OF NUCLEIC ACIDS
KR102761791B1 (ko) 2017-06-26 2025-02-05 더 브로드 인스티튜트, 인코퍼레이티드 표적화된 핵산 편집을 위한 crispr/cas-아데닌 데아미나아제 기반 조성물, 시스템 및 방법
US20200140896A1 (en) 2017-06-30 2020-05-07 Novartis Ag Methods for the treatment of disease with gene editing systems
US10392616B2 (en) 2017-06-30 2019-08-27 Arbor Biotechnologies, Inc. CRISPR RNA targeting enzymes and systems and uses thereof
CN111164211B (zh) 2017-07-18 2024-08-02 杰特贝林基因治疗股份有限公司 用于治疗β-血红蛋白病的组合物和方法
BR112020001653A2 (pt) 2017-07-26 2020-07-21 Forty Seven, Inc. anticorpos anti-sirp-alfa e métodos relacionados
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
CA3073448A1 (en) 2017-08-23 2019-02-28 The General Hospital Corporation Engineered crispr-cas9 nucleases with altered pam specificity
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
US10849924B2 (en) 2017-09-26 2020-12-01 New York Medical College Compositions and methods for restoring endothelial glycocalyx
WO2019071274A1 (en) 2017-10-06 2019-04-11 Oregon Health & Science University Compositions and methods for editing rna
KR20250107288A (ko) 2017-10-16 2025-07-11 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
AU2018353533A1 (en) 2017-10-17 2020-05-28 Rhizen Pharmaceuticals Sa CRAC channel modulators for treating esophageal cancer
WO2019084053A1 (en) 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
KR20200069364A (ko) 2017-10-24 2020-06-16 마젠타 테라퓨틱스 인코포레이티드 Cd117+ 세포의 고갈을 위한 조성물 및 방법
WO2019084057A2 (en) 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
MA50849A (fr) 2017-10-26 2020-09-02 Vertex Pharma Substances et procédés pour le traitement d'hémoglobinopathies
WO2019082124A1 (en) 2017-10-26 2019-05-02 Rhizen Pharmaceuticals Sa COMPOSITION AND METHOD FOR THE TREATMENT OF LARGE B-CELL DIFFUSED LYMPHOMA
JP2021501160A (ja) 2017-10-30 2021-01-14 ルヒゼン ファーマスティカルズ エスエー 血液がんおよび固形がんの処置のためのカルシウム放出活性化カルシウムチャネルモジュレーター
CA3084905A1 (en) 2017-12-06 2019-06-13 Rhizen Pharmaceuticals Sa Composition and method for treating peripheral t-cell lymphoma and cutaneous t-cell lymphoma
WO2019113437A1 (en) 2017-12-08 2019-06-13 The Board Of Trustees Of The Leland Stanford Junior University Hematopoietic stem cell engraftment
EP3724326A1 (en) 2017-12-11 2020-10-21 Editas Medicine, Inc. Cpf1-related methods and compositions for gene editing
WO2019126709A1 (en) 2017-12-22 2019-06-27 The Broad Institute, Inc. Cas12b systems, methods, and compositions for targeted dna base editing
CN109957569B (zh) 2017-12-22 2022-10-25 苏州齐禾生科生物科技有限公司 基于cpf1蛋白的碱基编辑系统和方法
GB201802201D0 (en) 2018-02-09 2018-03-28 Ultrahuman Five Ltd Binding agents
EP3762496A2 (en) 2018-03-07 2021-01-13 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
KR102775717B1 (ko) 2018-03-13 2025-03-06 암젠 인크 질량 분광 분석을 위한 폴리펩티드의 순차적 소화
EP4321870B1 (en) 2018-03-13 2025-07-30 Amgen Inc. Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis
KR102907245B1 (ko) 2018-03-14 2026-01-05 에디타스 메디신, 인코포레이티드 혈색소병증 치료를 위한 시스템 및 방법
CA3093701A1 (en) 2018-03-14 2019-09-19 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
US20210363518A1 (en) 2018-03-19 2021-11-25 University Of Massachusetts Modified guide rnas for crispr genome editing
US11898203B2 (en) 2018-04-17 2024-02-13 The General Hospital Corporation Highly sensitive in vitro assays to define substrate preferences and sites of nucleic-acid binding, modifying, and cleaving agents
AU2019265019B2 (en) 2018-05-11 2025-11-06 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
KR20250133482A (ko) 2018-05-11 2025-09-05 빔 테라퓨틱스, 인크. 프로그래밍가능한 염기 편집기 시스템을 이용하여 단일 뉴클레오티드 다형성을 편집하는 방법
CN119570787A (zh) 2018-05-11 2025-03-07 比姆医疗股份有限公司 使用可编程碱基编辑器系统遏止病原性突变的方法
CN112384230A (zh) 2018-05-14 2021-02-19 瑟姆巴股份有限公司 用于自身免疫障碍的基因编辑
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
JP2021526525A (ja) 2018-06-07 2021-10-07 マジェンタ セラピューティクス インコーポレイテッドＭａｇｅｎｔａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 抗体薬物コンジュゲート（ａｄｃｓ）を用いた治療方法
CA3108281A1 (en) 2018-08-03 2020-02-06 Beam Therapeutics Inc. Multi-effector nucleobase editors and methods of using same to modify a nucleic acid target sequence
EP3841203A4 (en) 2018-08-23 2022-11-02 The Broad Institute Inc. CAS9 VARIANTS WITH NON-CANONICAL PAM SPECIFICITIES AND THEIR USES
US20210347848A1 (en) 2018-08-31 2021-11-11 ALX Oncology Inc. Decoy polypeptides
EP3847254A4 (en) 2018-09-07 2022-08-10 Beam Therapeutics Inc. COMPOSITIONS AND METHODS FOR DELIVERING A NUCLEOBASE EDITING SYSTEM
GB201815670D0 (en) 2018-09-26 2018-11-07 Univ Oxford Innovation Ltd Protein editing
CN109295186B (zh) 2018-09-30 2023-10-03 中山大学 一种基于全基因组测序检测腺嘌呤单碱基编辑系统脱靶效应的方法及其在基因编辑中的应用
CA3114668A1 (en) 2018-10-01 2020-04-09 The Board Of Trustees Of The Leland Stanford Junior University High specificity and sensitivity immunosorbent diagnostic assays with simultaneous resolution of multiple antibody isotypes
KR102716514B1 (ko) 2018-10-10 2024-10-15 주식회사 노벨티노빌리티 신규 항-c-KIT 항체
US20200376135A1 (en) 2018-10-23 2020-12-03 Magenta Therapeutics, Inc. Fc silenced antibody drug conjugates (adcs) and uses thereof
AU2019366960A1 (en) 2018-10-23 2021-05-27 Regeneron Pharmaceuticals, Inc. Fc silenced antibody drug conjugates (ADCs) and uses thereof
WO2020092655A1 (en) 2018-10-30 2020-05-07 Magenta Therapeutics, Inc. Methods for allogeneic hematopoietic stem cell transplantation
EA202190986A1 (ru) 2018-11-26 2021-12-14 Фоти Севен, Инк. ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К c-Kit
EP3886869A4 (en) 2018-11-28 2022-07-06 Forty Seven, Inc. GENETICALLY MODIFIED ABLATION-RESISTANT HSPCS
EP3887521A1 (en) 2018-11-29 2021-10-06 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
AU2019396614B2 (en) 2018-12-14 2025-07-10 Amgen Inc. System suitability method for use with protein concentration determination by slope
AU2020215730A1 (en) 2019-01-31 2021-07-29 Beam Therapeutics Inc. Nucleobase editors having reduced non-target deamination and assays for characterizing nucleobase editors
WO2020160517A1 (en) 2019-01-31 2020-08-06 Beam Therapeutics Inc. Nucleobase editors having reduced off-target deamination and methods of using same to modify a nucleobase target sequence
US11946040B2 (en) 2019-02-04 2024-04-02 The General Hospital Corporation Adenine DNA base editor variants with reduced off-target RNA editing
KR20210126680A (ko) 2019-02-13 2021-10-20 빔 테라퓨틱스, 인크. 알파-1 항트립신 결핍증을 치료하기 위한 조성물 및 방법
JP7693552B2 (ja) 2019-02-13 2025-06-17 ビーム セラピューティクス インク． アデノシンデアミナーゼ塩基エディターおよびそれを用いて標的配列中の核酸塩基を改変する方法
US20220098593A1 (en) 2019-02-13 2022-03-31 Beam Therapeutics Inc. Splice acceptor site disruption of a disease-associated gene using adenosine deaminase base editors, including for the treatment of genetic disease
WO2020168088A1 (en) 2019-02-13 2020-08-20 Beam Therapeutics Inc. Compositions and methods for treating glycogen storage disease type 1a
CN120174005A (zh) 2019-02-13 2025-06-20 比姆医疗股份有限公司 具有用于修饰靶标序列中核碱基的腺苷脱氨酶碱基编辑器的经修饰的免疫细胞
US20230140953A1 (en) 2019-02-13 2023-05-11 Beam Therapeutics Inc. Methods of editing a disease-associated gene using adenosine deaminase base editors, including for the treatment of genetic disease
CA3128755C (en) 2019-02-13 2024-06-04 Beam Therapeutics Inc. Compositions and methods for treating hemoglobinopathies
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
JP2022531141A (ja) 2019-04-24 2022-07-06 マジェンタ セラピューティクス インコーポレイテッド 遺伝子治療のコンディショニング方法
EP3959242A4 (en) 2019-04-24 2023-09-13 Magenta Therapeutics, Inc. ANTRACYCLINE ANTIBODY-DRUG CONJUGATES AND THEIR USES
EP3958902A4 (en) 2019-04-24 2023-01-25 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODIES AND THEIR USES
EP3958909A4 (en) 2019-04-24 2024-01-10 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODY DRUG CONJUGATES AND USES THEREOF
NZ781538A (en) 2019-04-24 2025-12-19 Heidelberg Pharma Res Gmbh Amatoxin antibody-drug conjugates and uses thereof
JP2022530443A (ja) 2019-04-24 2022-06-29 マジェンタ セラピューティクス インコーポレイテッド 抗ｃｄ１１７抗体薬物複合体およびその使用
WO2020219748A2 (en) 2019-04-24 2020-10-29 Magenta Therapeutics, Inc. Anti-cd117 antibodies and uses thereof
CA3137568A1 (en) 2019-04-25 2020-10-29 Actinium Pharmaceuticals, Inc. Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseases
CN110042124A (zh) 2019-04-25 2019-07-23 国家卫生健康委科学技术研究所 基因组碱基编辑增加人红细胞中胎儿血红蛋白水平的试剂盒及应用
AU2020279751A1 (en) 2019-05-21 2021-12-02 Beam Therapeutics Inc. Methods of editing a single nucleotide polymorphism using programmable base editor systems
EP3976658A4 (en) 2019-05-24 2023-06-07 Forty Seven, Inc. Regimes for co-administration of immunotherapeutic agents against c-kit and cd47
EP3983405A4 (en) 2019-06-12 2023-06-07 Ontario Institute for Cancer Research (OICR) NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) INHIBITING CONJUGATES AND USES THEREOF
KR102258713B1 (ko) 2019-07-31 2021-05-31 한양대학교 산학협력단 사이토신 염기교정용 조성물 및 이의 용도
EP4003375A4 (en) 2019-07-31 2023-09-06 Forty Seven, Inc. DEPLETION DIETS FOR MODIFIED T CELL OR NK CELL THERAPY
EP4022051A4 (en) 2019-08-29 2024-01-10 Beam Therapeutics Inc. COMPOSITIONS AND METHODS FOR NON-TOXIC CONDITIONING
GB201912681D0 (en) 2019-09-04 2019-10-16 Eth Zuerich Bispecific binding agent that binds to cd117/c-kit and cd3
AU2020344547A1 (en) 2019-09-09 2022-03-24 Beam Therapeutics Inc. Novel nucleobase editors and methods of using same
EP3792346B1 (en) 2019-09-13 2023-07-26 Miltenyi Biotec B.V. & Co. KG Method for the generation of a cell composition of ventral midbrain dopaminergic progenitor cells
AU2020348295A1 (en) 2019-09-16 2022-04-07 Insmed Incorporated Anti-stem cell factor antibodies and methods of use thereof
AU2020466994A1 (en) 2019-09-17 2022-04-21 Rutgers, The State University Of New Jersey Highly efficient DNA base editors mediated by RNA-aptamer recruitment for targeted genome modification and uses thereof
CN112125915A (zh) 2019-09-18 2020-12-25 四川百利药业有限责任公司 一种喜树碱衍生物及其偶联物
EP4017980A4 (en) 2019-09-30 2024-08-07 The Children's Medical Center Corporation BCL11A GUIDE AND BASIC EDITOR DISTRIBUTION
IL292378A (en) 2019-10-21 2022-06-01 Rhizen Pharmaceuticals Ag Preparations that include a dhodh inhibitor for the treatment of acute myeloid leukemia
NL2024163B1 (en) 2019-11-05 2021-07-20 Univ Of Salamanca Means and methods for multiparameter cytometry-based leukocyte subsetting.
CA3161606A1 (en) 2019-11-15 2021-05-20 Neoprogen, Inc. Immortalized cardiac stem cells for cardiac repair
EP3825330A1 (en) 2019-11-19 2021-05-26 International-Drug-Development-Biotech Anti-cd117 antibodies and methods of use thereof
KR102772859B1 (ko) 2019-11-25 2025-02-27 주식회사 노벨티노빌리티 c-kit에 대한 항체 및 이의 용도
EP4077652A1 (en) 2019-12-20 2022-10-26 Limagrain Europe Improving efficiency of base editing using typev crispr enzymes
EP4100519A2 (en) 2020-02-05 2022-12-14 The Broad Institute, Inc. Adenine base editors and uses thereof
EP4100032B1 (en) 2020-02-05 2025-10-15 The Broad Institute, Inc. Gene editing methods for treating spinal muscular atrophy
WO2021163587A1 (en) 2020-02-13 2021-08-19 Beam Therapeutics Inc. Compositions and methods for engraftment of base edited cells
GB202003129D0 (en) 2020-03-04 2020-04-15 Hansa Biopharma AB Conditioning regimen for transplant of stem cells
JP2023517890A (ja) 2020-03-04 2023-04-27 スージョウ チー バイオデザイン バイオテクノロジー カンパニー リミテッド 改善されたシトシン塩基編集システム
AU2021239929A1 (en) 2020-03-16 2022-10-13 Crispr Therapeutics Ag T-cell bispecific binding proteins
JP2023518395A (ja) 2020-03-19 2023-05-01 インテリア セラピューティクス，インコーポレイテッド 指向性ゲノム編集のための方法及び組成物
EP4132951A4 (en) 2020-04-09 2025-06-11 Verve Therapeutics, Inc. CHEMICALLY MODIFIED GENE EDITING GUIDE RNAS WITH CAS12B
WO2021211734A1 (en) 2020-04-15 2021-10-21 The Regents Of The University Of California Compositions and methods for treatment
US20230279438A1 (en) 2020-05-13 2023-09-07 Inserm (Institut National De La Santé Et La Recherche Médicale) Base editing approaches for the treatment of betahemoglobinopathies
US20230227847A1 (en) 2020-05-27 2023-07-20 Universität Zürich Viral vectors expressing therapeutic proteins specifically in myeloid cells and microglia
AU2021289927A1 (en) 2020-06-08 2023-01-19 Systimmune, Inc. Camptothecin drug having high-stability hydrophilic connecting unit and conjugate thereof
WO2022008935A1 (en) 2020-07-10 2022-01-13 Horizon Discovery Limited Method for producing genetically modified cells
WO2022011458A1 (en) 2020-07-13 2022-01-20 Ontario Institute For Cancer Research (Oicr) Nicotinamide phosphoribosyltransferase (nampt) inhibitor-conjugates and uses thereof
US20240247242A1 (en) 2020-07-15 2024-07-25 LifeEDIT Therapeutics, Inc. Uracil stabilizing proteins and active fragments and variants thereof and methods of use
KR20230110243A (ko) 2020-08-14 2023-07-21 오차드 테라퓨틱스 (유럽) 리미티드 유전성 혈관부종을 치료하거나 예방하기 위한 조성물 및 방법
JP2023538071A (ja) 2020-08-20 2023-09-06 アンブルックス，インコーポレイテッド 抗体－ｔｌｒアゴニストコンジュゲート、その方法及び使用
KR20230061421A (ko) 2020-08-29 2023-05-08 아르제넥스 비브이 Bcl-2 억제제에 대한 감소된 민감도를 가진 환자를 치료하는 방법
JP2023540797A (ja) 2020-09-11 2023-09-26 メタゲノミ，インコーポレイテッド 塩基編集酵素
MX2023002848A (es) 2020-09-11 2023-03-22 Lifeedit Therapeutics Inc Enzimas modificadoras del acido desoxirribonucleico (adn) y fragmentos activos y sus variantes y metodos de uso.
CA3198671A1 (en) 2020-10-14 2022-04-21 Beam Therapeutics Inc. Compositions and methods for treating glycogen storage disease type 1a
WO2022081828A1 (en) 2020-10-16 2022-04-21 The Board Of Trustees Of The Leland Stanford Junior University Hematopoietic stem cell engraftment with a combination of agents
IT202000028688A1 (it) 2020-11-27 2022-05-27 Consiglio Nazionale Ricerche Varianti della citidina deaminasi per l’editazione di basi
CN114752629B (zh) 2020-12-28 2025-08-19 华东师范大学 一种针对细胞中单个或多个基因进行基因编辑的方法、产品和应用
EP4274897A4 (en) 2021-01-08 2025-03-05 The General Hospital Corporation GENOMEDITING APPROACHES TO THE TREATMENT OF SPINAL MUSCLE ATROPHY
US20240360414A1 (en) 2021-01-15 2024-10-31 St. Jude Children's Research Hospital, Inc. Systems and Methods for Base Editing Of HBG1/2 Gene Promoter and Fetal Hemoglobin Induction
US20240327859A1 (en) 2021-07-02 2024-10-03 University Of Maryland, College Park Cytidine deaminases and methods of genome editing using the same
US20240352439A1 (en) 2021-09-03 2024-10-24 The University Of Chicago Polypeptides and methods for modifying nucleic acids
IL311607A (en) 2021-09-22 2024-05-01 Verve Therapeutics Inc PCSK9 or ANGPTL3 gene editing and preparations and methods for using them to treat the disease
US20230105319A1 (en) 2021-09-24 2023-04-06 Crispr Therapeutics Ag PRODRUG INCORPORATED sgRNA SYNTHESIS
WO2023125814A1 (zh) 2021-12-29 2023-07-06 华东师范大学 腺嘌呤脱氨酶及其应用
CN119013310A (zh) 2022-02-17 2024-11-22 正序(上海)生物科技有限公司 具有改善的编辑精确度的突变的胞嘧啶脱氨酶
EP4540378A1 (en) 2022-06-20 2025-04-23 CRISPR Therapeutics AG Base editing proteins and uses thereof
AU2023288909A1 (en) 2022-06-23 2025-01-09 Basf Agricultural Solutions Us Llc Diversifying base editing

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016528890A (ja) 2013-07-09 2016-09-23 プレジデント アンド フェローズ オブ ハーバード カレッジ ＣＲＩＳＰＲ／Ｃａｓ系を用いるゲノム編集の治療用の使用

Also Published As

Publication number Publication date
JP2025026840A (ja) 2025-02-26
JP2021523737A (ja) 2021-09-09
KR102852347B1 (ko) 2025-09-01
CN121555430A (zh) 2026-02-24
US20250108098A1 (en) 2025-04-03
AU2019265019B2 (en) 2025-11-06
CN112534054A (zh) 2021-03-19
CA3100019A1 (en) 2019-11-14
KR20250134703A (ko) 2025-09-11
US20220401530A1 (en) 2022-12-22
KR20210023831A (ko) 2021-03-04
US12133884B2 (en) 2024-11-05
AU2019265019A1 (en) 2020-11-26
CN112534054B (zh) 2025-10-28
AU2026200834A1 (en) 2026-02-26
EP3799603A4 (en) 2022-03-02
EP3799603A1 (en) 2021-04-07
WO2019217942A1 (en) 2019-11-14

Similar Documents

Publication Publication Date Title
JP7642531B2 (ja) プログラム可能塩基エディターシステムを用いて病原性アミノ酸を置換する方法
CN112601816B (zh) 使用可编程碱基编辑器系统遏止病原性突变的方法
CN112469446B (zh) 利用可编程碱基编辑器系统编辑单核苷酸多态性的方法
JP7717684B2 (ja) 新規核酸塩基エディター及びその使用方法
JP7646554B2 (ja) アルファ－１アンチトリプシン不全を治療するための組成物および方法
WO2021041885A2 (en) Compositions and methods for editing a mutation to permit transcription or expression
WO2023086953A1 (en) Compositions and methods for the treatment of hereditary angioedema (hae)
CN117729931A (zh) 用于治疗转甲状腺素蛋白淀粉样变性的组合物和方法
KR20240111821A (ko) B형 간염 바이러스 감염을 치료하기 위한 조성물 및 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220511

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230420

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230905

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240304

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241018

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241115

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250128

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250226

R150 Certificate of patent or registration of utility model

Ref document number: 7642531

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150